Brain tumour clinical trial title

Wrist Worn Trackers for monitoring physical activity in brain tumour patients (Study ID: 38629)

Brain tumour type

Schwannoma,  Pituitary,  Brain metastases,  Neuroblastoma,  oligoastrocytoma,  Ependymoma,  Meningioma,  Medulloblastoma,  Glioma,  Glioblastoma,  Astrocytoma,  Anaplastic oligodendroglioma,  Anaplastic glioma,  Anaplastic astrocytoma, 



Most patient with brain tumours develop functional disturbance (weakness, balance problems, etc.) as part of their illness, and report fatigue as being a significant effect of the tumour and/or treatments. However, we have little detailed information of the impact of treatment on patient activity levels, nor how this relates to accepted measures of QoL and toxicity of treatment. We aim to use patient-worn devices to better measure changes in activity levels as part of acute treatment-related toxicity and also monitor patients for signs of functional decline, with the intention of then being able to offer second-line treatment sooner. However, in order to achieve these we need to understand normal changes in activity over time as patients undergo treatment. Recent developments in technology allow us the opportunity to gather high-resolution electronic data directly from the patient, using patient-worn wristband devices. These will allow us to monitor patient activity, and we will then examine the correlation between absolute levels and changes in patient activity levels with conventional measures of toxicity, HRQoL and disease progression/response. Previous work has used patient-worn sensors to assess activity and gait in patients who have had strokes, and in those with multiple myeloma, and we have experience of using patient-worn electronic sensors in patients undergoing bariatric surgery. This is the first study in the world to assess the use of patient worn accelerometers in patients with brain tumours undergoing oncological treatments and follow up. We will also assess physical activity in matched healthy volunteer's (main caregiver) to correlate any changes, and allow us to compare physical activity patterns.

Date added: 12th January 2019

Open/Closed: Open

Trial ends: July 2022


Charing Cross Hospital

Contact details

Dr Matthew Williams :
Department of Radiotherapy
Fulham Palace Road
W6 8RF
Telephone: 02033111234

Find on Google maps »